Table 5.
Fractional target attainment (FTA) for various dosing regimens of ampicillin-sulbactam to attain fT>MIC ≥ 60% for the sulbactam component against A. baumannii
| Ampicillin-sulbactam dosing regimens | FTA (%) by bacteria and SeCr (mg/dL) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| A. baumannii | ||||||||||
| SeCr 6 | SeCr 2 | SeCr 1.5 | SeCr 1 | SeCr 0.7 | ||||||
| a | b | a | b | a | b | a | b | a | b | |
| Empiric FTAs against the whole minimum inhibitory concentration (MIC) distribution | ||||||||||
| 3 g q24-h bolus | × | × | − | − | − | − | − | − | − | − |
| 3 g q24-h infusion | × | × | − | − | − | − | − | − | − | − |
| 1.5 g q24-h bolus | × | × | − | − | − | − | − | − | − | − |
| 1.5 g q24-h infusion | × | × | − | − | − | − | − | − | − | − |
| 3 g q12-h bolus | − | − | × | × | − | − | − | − | − | − |
| 3 g q12-h infusion | − | − | × | × | − | − | − | − | − | − |
| 1.5 g q12-h bolus | − | − | × | × | − | − | − | − | − | − |
| 1.5 g q12-h infusion | − | − | × | × | − | − | − | − | − | − |
| 3 g q8-h bolus | − | − | − | − | × | × | × | × | × | × |
| 3 g q8-h infusion | − | − | − | − | × | × | × | × | × | × |
| 1.5 g q6-h bolus | − | − | − | − | × | × | × | × | × | × |
| 1.5 g q6-h infusion | − | − | − | − | × | × | × | × | × | × |
| 3 g q6-h bolus | − | − | − | − | × | × | × | × | × | × |
| 3 g q6-h infusion | − | − | − | − | × | × | × | × | × | × |
| 1.5 g q6-h bolus | − | − | − | − | × | × | × | × | × | × |
| 1.5 g q6-h infusion | − | − | − | − | × | × | × | × | × | × |
| Directed FTAs against the susceptible strains | ||||||||||
| 3 g q24-h bolus | + | + | − | − | − | − | − | − | − | − |
| 3 g q24-h infusion | + | + | − | − | − | − | − | − | − | − |
| 1.5g q24-h bolus | + | + | − | − | − | − | − | − | − | − |
| 1.5g q24-h infusion | + | + | − | − | − | − | − | − | − | − |
| 3 g q12-h bolus | − | − | × | + | − | − | − | − | − | − |
| 3 g q12-h infusion | − | − | + | + | − | − | − | − | − | − |
| 1.5 g q12-h bolus | − | − | × | × | + | − | − | − | − | − |
| 1.5 g q12-h infusion | − | − | × | + | + | − | − | − | − | − |
| 3 g q8-h bolus | − | − | + | + | + | + | × | × | × | × |
| 3 g q8-h infusion | − | − | − | − | + | + | + | + | + | + |
| 1.5 g q8-h bolus | − | − | − | − | × | × | × | × | × | × |
| 1.5 g q8-h infusion | − | − | − | − | + | + | × | + | × | × |
| 3 g q6-h bolus | − | − | − | − | + | + | + | + | × | × |
| 3 g q6-h infusion | − | − | − | − | + | + | + | + | + | + |
| 1.5 g q6-h bolus | − | − | − | − | × | + | × | × | × | × |
| 1.5 g q6-h infusion | − | − | − | − | + | + | + | + | + | + |
SeCr serum creatinine; a, simulation at the first dosing regimen; b, simulation at the fifth dosing regimens; −, not simulated; +, could attain FTA ≥ 95%; ×, could not attain FTA ≥ 95%; q24 h, 12 h, 8 h, 6 h indicates the dose is given every 24 h, 12 h, 8 h, 6 h, respectively